Mutations can interfere with posttranscriptional expression of the HLA-A and -B genes. B-lymphoblastoid cells that contain one copy of the major histocompatibility complex (MHC) were subjected to mutagenesis and immunoselection for MHC antigen-loss mutants. Some mutations partially reduced surface expression of HLA-A and eliminated HLA-B expression concurrently, although the HLA-A and -B genes were present and transcribed. Antigen expression was fully restored in hybrids of these mutants with other Blymphoblastoid cells. Therefore, normal cell surface expression of the HLA-A and -B antigens on B lymphoblasts requires (1) execution of at least one trans-active step in the production of the antigens after transcription of the HLA-A and -B genes or (it) association ofthe class I antigens with other molecules. DNA analysis of one mutant suggests the possibility that a locus required for the normal expression of the HLA-A and -B antigens is located between the MHC complement genes and the HLA-DP all locus.f32m deficiency results in failure of class I a chains to associate with the cell membrane in mouse (e.g., ref. 15) and human (e.g., refs. 16 and 17) cells. Expression of class I antigens on lymphocytes is also deficient in humans who are homozygous for recessive mutations that cause the "bare lymphocyte syndrome," although the genes and potential for their expression are present. The consequence in some cases is defective B-cell maturation, combined immunodeficiency disease, and early death (18-22), whereas pathological manifestations are less severe in other cases (23).This paper describes a unique kind of derangement in class I antigen expression. Mutagenic treatment of human Blymphoblastoid cell lines (B-LCLs) resulted in isolation of mutants that had simultaneously reduced expressions of the A and B antigens even though the HLA-A and -B and the 32m genes were present and transcribed. We believe these class

No abstract

A collection of human B lymphoblastoid cell lines (LCLs) was used to map two genetic sequences for which polymorphism had not been identified: human prolactin (PRL) and tumor necrosis factor-beta (TNFB). The LCLs have overlapping deletions on chromosome 6p produced by gamma-irradiation of LCL 721. After using two chromosome 6p sequences for which LCL 721 is heterozygous to validate our scanning densitometry (SD) method for inferring gene copy number, SD was used to map TNFB and PRL. TNFB maps to the interval between the C4 complement and HLA-B loci within the MHC on chromosome 6p. PRL lies within the 6p21.3-6p22.2 interval distal to HLA-C. We found that LCL 721 is heterozygous for PRL DNA fragment lengths generated by HpaII but not MspI digestion, indicating that the two copies of PRL in LCL 721 are differentially methylated. This novel methylation RFLP was used to corroborate the region PRL assignment.

No abstract

Seven allospecific cytotoxic T lymphocyte (CTL) clones derived from DPw2-specific bulk populations were characterized by three approaches to obtain a more detailed understanding of the T cell recognition of the HLA-DPw2 molecule. All seven of the clones were DPw2 specific and indistinguishable in specificity by three approaches: (a) patterns of lysis of panels of targets from normal donors; (b) inhibition of lysis by anti-class II monoclonal antibodies (mAb); (c) lysis of mutant lymphoblastoid B cell lines (LCL) with isolated loss of DP2 alpha or DP2 beta gene expression (as a result of selection for resistance to DPw2-specific CTL). However, only four of the seven CTL clones (which we designate "orthodox") lysed all mutant DPw2+ LCL tested; the other three ("heterodox") CTL clones showed reduced or no lysis of particular LCL which expressed DPw2 but had been mutagenized and selected for loss of DR expression. Cold target blocking experiments with the mutant LCL confirmed differences in: (a) specificity among CTL clones and (b) CTL-defined phenotype among serologically indistinguishable DR-DPw2+ mutant LCL. Differences were not explained by different levels of DP expression by the mutant LCL. Given the nature of the mutagens and mutations, it is highly improbable that point mutations in DP account for differences in recognition. These data suggest that non-DP HLA genes influence recognition by some DP-specific clones, potentially due to corecognition of HLA-DR alpha or another non-DP HLA product in the context of a DPw2 alpha/beta dimer.